ALLTogether by https://padlet.com/catleeman/gkqmacmocy7cdvn Improving Outcomes for Children & Young People with ALL en-us 2022-05-11 10:45:25 UTC 2025-09-24 13:53:29 UTC hello@padlet.com https://padlet.net/icons/png/1f932.png catleeman https://padlet.com/catleeman/gkqmacmocy7cdvn/wish/2179471182 2022-05-11 13:58:15 UTC https://padlet.com/catleeman/gkqmacmocy7cdvn/wish/2179471182 catleeman https://padlet.com/catleeman/gkqmacmocy7cdvn/wish/2179517572  Inclusion Criteria:
 
  • Patients with newly diagnosed T-lineage or precursor B-cell ALL.  
  • Age between 1-29 years  
  • Written informed consent from parents/guardians and patient 

 Exclusion Criteria:  

  • Age ≥46 years at diagnosis. 
  • Age <365 days at diagnosis. 
  • Patients with a previous malignant diagnosis. 
  • Relapse of ALL
  • Mature B-ALL 
  • Philadelphia positive ALL 
  • Treatment with systemic corticosteroids for more than one week and/or other chemotherapeutic agents within 4 weeks prior to diagnosis. 
]]> 2022-05-11 14:23:02 UTC https://padlet.com/catleeman/gkqmacmocy7cdvn/wish/2179517572 Research Question... catleeman https://padlet.com/catleeman/gkqmacmocy7cdvn/wish/2185858434 To improve the outcome of children and young adults with ALL by testing a number of randomised and non-randomised interventions.

These interventions are designed to either: 
  • - decrease the risk of serious side-effects and therapy
  • - decrease the risk of relapse for patients at high risk of relapse and therapy 
  • - decrease the risk of relapse and reduce toxic side-effects for patients with genetic lesions targetable by Tyrosine-kinase inhibition by the addition of Imatinib to standard chemotherapy. 
  • - decrease the risk of serious side-effects for patients with high-risk B-cell precursor ALL by making them available for experimental immunotherapy 
]]> 2022-05-16 14:47:03 UTC https://padlet.com/catleeman/gkqmacmocy7cdvn/wish/2185858434 PEGAsp pre-dose sampling levels eliselongworth1 https://padlet.com/catleeman/gkqmacmocy7cdvn/wish/2216083324 Beckie is putting together an SOP and sampling box containing all the necessary EDTA bottles, forms and packaging. She will deliver them to each POSCU in the new year and be on hand to help with any questions. ]]> 2022-06-09 09:16:17 UTC https://padlet.com/catleeman/gkqmacmocy7cdvn/wish/2216083324 Key Contact Details eliselongworth1 https://padlet.com/catleeman/gkqmacmocy7cdvn/wish/2216087611 Research Nurses - Elise Longworth & Beckie Weaver 01865 234982 (Becca Walker on MAT until May 2023)
elise.longworth@ouh.nhs.uk
rebecca.weaver@ouh.nhs.uk 

Toxicity/Admission reporting - paedhaem.oncresearch@nhs.net

Kamran's Ward - 01865 234068]]> 2022-06-09 09:20:58 UTC https://padlet.com/catleeman/gkqmacmocy7cdvn/wish/2216087611 Feedback eliselongworth1 https://padlet.com/catleeman/gkqmacmocy7cdvn/wish/2217408076 Please leave any thoughts, ideas or feedback (it is anonymized so don't be afraid!) so I can make this a success!]]> 2022-06-10 11:43:38 UTC https://padlet.com/catleeman/gkqmacmocy7cdvn/wish/2217408076 eliselongworth1 https://padlet.com/catleeman/gkqmacmocy7cdvn/wish/2217452804 2022-06-10 12:37:19 UTC https://padlet.com/catleeman/gkqmacmocy7cdvn/wish/2217452804 AQ teaching 14.06.2022 eliselongworth1 https://padlet.com/catleeman/gkqmacmocy7cdvn/wish/2220910102 2022-06-14 15:05:07 UTC https://padlet.com/catleeman/gkqmacmocy7cdvn/wish/2220910102 PEGAsparaginase Information Sheet catleeman https://padlet.com/catleeman/gkqmacmocy7cdvn/wish/2233275922 2022-06-29 09:18:11 UTC https://padlet.com/catleeman/gkqmacmocy7cdvn/wish/2233275922 TYA in ALL2G eliselongworth1 https://padlet.com/catleeman/gkqmacmocy7cdvn/wish/2240906553 TYA who fulfil SR criteria will be EXEMPT from the randomisation (R1)

TYA with IR Stratification will be EXEMPT from the IR-Low arm. All IR TYA will follow the IR-High therapy

TYA >25yrs will omit the PEG-Asparaginase dose on day 4. 1st dose will be on D18 with the D4 dose added in later in treatment (D113)]]> 2022-07-11 08:59:05 UTC https://padlet.com/catleeman/gkqmacmocy7cdvn/wish/2240906553 ALL2G Backbone eliselongworth1 https://padlet.com/catleeman/gkqmacmocy7cdvn/wish/2241915404 2022-07-12 14:40:42 UTC https://padlet.com/catleeman/gkqmacmocy7cdvn/wish/2241915404 Risk Stratification eliselongworth1 https://padlet.com/catleeman/gkqmacmocy7cdvn/wish/2241917347 2022-07-12 14:43:47 UTC https://padlet.com/catleeman/gkqmacmocy7cdvn/wish/2241917347 CiprolPAL SIV eliselongworth1 https://padlet.com/catleeman/gkqmacmocy7cdvn/wish/2320666278 2022-09-30 07:48:36 UTC https://padlet.com/catleeman/gkqmacmocy7cdvn/wish/2320666278 eliselongworth1 https://padlet.com/catleeman/gkqmacmocy7cdvn/wish/2360545543 2022-10-28 12:33:41 UTC https://padlet.com/catleeman/gkqmacmocy7cdvn/wish/2360545543 SAE reporting in ALLTogether eliselongworth1 https://padlet.com/catleeman/gkqmacmocy7cdvn/wish/2420317069  SAE reporting in ALLTogether requires documentation of Toxicities of Special Interest at specific timepoints. 

Please continue to inform paedhaem.oncresearch@nhs.net of all ALL admissions. Any specific information on the toxicities listed above (exact temp, blood results etc) is so helpful for our reporting and source data. ]]> 2022-12-14 09:36:20 UTC https://padlet.com/catleeman/gkqmacmocy7cdvn/wish/2420317069 ALL2G presentation from SACT eliselongworth1 https://padlet.com/catleeman/gkqmacmocy7cdvn/wish/2420321977 2022-12-14 09:41:39 UTC https://padlet.com/catleeman/gkqmacmocy7cdvn/wish/2420321977